T. Rowe Price Associates’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $34.6M | Buy |
3,033,844
+120,476
| +4% | +$1.37M | ﹤0.01% | 829 |
|
|
2025
Q1 | $34.6M | Sell |
2,913,368
-93,959
| -3% | -$1.12M | ﹤0.01% | 824 |
|
|
2024
Q4 | $56.7M | Sell |
3,007,327
-61,634
| -2% | -$1.16M | 0.01% | 717 |
|
|
2024
Q3 | $69M | Buy |
3,068,961
+233,842
| +8% | +$5.25M | 0.01% | 659 |
|
|
2024
Q2 | $59.2M | Buy |
2,835,119
+638,950
| +29% | +$13.3M | 0.01% | 670 |
|
|
2024
Q1 | $32.3M | Sell |
2,196,169
-193,797
| -8% | -$2.85M | ﹤0.01% | 841 |
|
|
2023
Q4 | $24.7M | Buy |
2,389,966
+11,988
| +0.5% | +$124K | ﹤0.01% | 904 |
|
|
2023
Q3 | $18.7M | Sell |
2,377,978
-1,895
| -0.1% | -$14.9K | ﹤0.01% | 929 |
|
|
2023
Q2 | $23.8M | Sell |
2,379,873
-204,878
| -8% | -$2.05M | ﹤0.01% | 891 |
|
|
2023
Q1 | $23M | Sell |
2,584,751
-668,985
| -21% | -$5.94M | ﹤0.01% | 885 |
|
|
2022
Q4 | $35.7M | Sell |
3,253,736
-352,616
| -10% | -$3.87M | 0.01% | 758 |
|
|
2022
Q3 | $47M | Sell |
3,606,352
-1,014,471
| -22% | -$13.2M | 0.01% | 665 |
|
|
2022
Q2 | $58.5M | Sell |
4,620,823
-185,466
| -4% | -$2.35M | 0.01% | 827 |
|
|
2022
Q1 | $67.3M | Sell |
4,806,289
-64,795
| -1% | -$908K | 0.01% | 862 |
|
|
2021
Q4 | $141M | Buy |
4,871,084
+152,207
| +3% | +$4.41M | 0.01% | 658 |
|
|
2021
Q3 | $141M | Buy |
4,718,877
+667,399
| +16% | +$20M | 0.01% | 660 |
|
|
2021
Q2 | $107M | Buy |
4,051,478
+957,773
| +31% | +$25.4M | 0.01% | 755 |
|
|
2021
Q1 | $96.2M | Buy |
3,093,705
+2,502,069
| +423% | +$77.8M | 0.01% | 791 |
|
|
2020
Q4 | $19.5M | Buy |
591,636
+28,890
| +5% | +$950K | ﹤0.01% | 1231 |
|
|
2020
Q3 | $19.6M | Buy |
+562,746
| New | +$19.6M | ﹤0.01% | 1160 |
|